| Web: | mayocliniclabs.com |
|---|---|
| Email: | mcl@mayo.edu |
| Telephone: | 800-533-1710 |
| International: | +1 855-379-3115 |
| Values are valid only on day of printing | |
| Web: | mayocliniclabs.com |
|---|---|
| Email: | mcl@mayo.edu |
| Telephone: | 800-533-1710 |
| International: | +1 855-379-3115 |
| Values are valid only on day of printing | |
For patients experiencing mild cognitive impairment (MCI) due to Alzheimer’s disease, accurate diagnosis before dementia sets in can help them prepare for what lies ahead. Diagnosis at the onset of MCI supports integration of lifestyle medicine, facilitates access to disease-modifying therapies, and enables entry into clinical trials.
Our innovative plasma biomarker testing can provide clarity to patients in the initial stages of cognitive decline related to Alzheimer’s disease. Noninvasive and intended for patients aged 50 and above, our assays evaluate for biomarkers in the blood associated with amyloid beta (Aβ) pathology in the brain using clinically supported protein phosphorylated Tau 217 (p-Tau217) and biomarker ratios.
A proactive testing approach
Research on Alzheimer’s disease laboratory testing continues to reveal insights on the role of fluid biomarkers in detecting amyloid pathology. Recognition of these biomarkers has resulted in the development of numerous biomarker evaluations. However, not all tests provide adequate sensitivity and/or specificity to enable diagnostic confidence. Nor do all tests evaluate for the most clinically relevant biomarkers.
The discovery that phosphorylated Tau proteins in the blood can identify brain amyloid pathology propelled development of plasma-based biomarker testing. Among fluid-based biomarkers known to predict Aβ pathology, p-Tau217 exhibits the highest levels of diagnostic accuracy. Our digital resource examines the evolution of plasma-based biomarker testing and explains how results from these evaluations can offer patients and their families hope for the future.
Download now
Fill out the form to download our digital guide on Alzheimer’s disease testing at Mayo Clinic Laboratories.
Dementia testing: Shifting the diagnostic paradigm*
*Available in English, Spanish, French, and Arabic
One-stop laboratory solution
In cases where blood-based biomarker testing does not yield definitive answers, Mayo Clinic Laboratories offers a comprehensive menu of dementia testing.
| Alzheimer's disease | Prion disease | Autoimmune dementia | Genetic testing | Nonspecific |
|---|---|---|---|---|
| p-Tau217 plasma biomarker testing | Rapidly progressive dementia | Autoimmune and paraneoplastic antibody testing | Apolipoprotein E genotyping | Neurofilament light chain |
| C2N plasma biomarker testing | Creutzfeldt-Jakob disease | Notch3 full gene analysis | ||
| Cerebrospinal fluid biomarker testing | Frontotemporal dementia and amyotrophic lateral sclerosis | |||
| C9orf72 hexanucleotide | ||||
| APP, PSEN1, PSEN2 |
Highlights
Mayo Clinic Laboratories has developed a cutting-edge suite of Alzheimer's disease testing. The newest assays use blood samples, avoiding the need for lumbar punctures to obtain cerebrospinal fluid. The testing suite exemplifies Mayo Clinic Laboratories' innovative business approach. As a platform company, Mayo Clinic is creating a diagnostics ecosystem to meet a wide range of testing needs and help physicians order the right tests for their patients.
In this episode of “Answers From the Lab,” host Bobbi Pritt, M.D., chair of the Division of Clinical Microbiology at Mayo Clinic, is joined by Alicia Algeciras-Schimnich,[...]
In this episode of “Answers From the Lab,” host Bobbi Pritt, M.D., chair of the Division of Clinical Microbiology at Mayo Clinic, is joined by William Morice II, M.D., Ph.D., CEO and president of Mayo Clinic Laboratories, to discuss the latest advancements in Alzheimer’s disease testing and treatment.
PACE/State of FL This webinar, with expert presenters having both extensive lab and clinical experience, will discuss the latest updates in Alzheimer’s disease diagnostic criteria as well as a comprehensive review of the laboratory testing landscape to help listeners better understand their options.
Rapidly progressive dementia (RPD) is an umbrella term covering many devasting conditions, including Creutzfeldt-Jakob disease (CJD). Gregory (Gregg) Day, M.D., explains how Mayo Clinic Laboratories' unique RPD evaluation and new CJD test help pinpoint diagnosis, to guide prognosis and treatment decisions.
In this episode of “Answers From the Lab,” host Bobbi Pritt, M.D., chair of the Division of Clinical Microbiology at Mayo Clinic, is joined by William Morice II, M.D., Ph.D., CEO and president of Mayo Clinic Laboratories. They discuss testing innovations for Alzheimer’s disease and cognitive impairments, and how laboratorians can responsibly help shape the future of healthcare.